Common Warts - Epidemiology Forecast to 2032

DelveInsight’s "Common Warts–Epidemiology Forecast–2032" report delivers an in-depth understanding of the Common Warts, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Common Warts Disease Understanding
Common warts, also known as verruca vulgaris, are caused by nonmalignant strains of human papillomavirus (HPV). They are typically benign lesions that rarely have malignant transformation. On the skin, they appear as rough, painless papules that can be grey or flesh-colored and are found on different body areas. Other subtypes of HPV that are associated with cervical cancer are not the same strains that cause verruca vulgaris (Pope et al., 2020).
Common warts are easy to distinguish from other types of warts, such as genital, filiform, and plantar warts. They are most commonly found on the hands or fingers, though they can also be found on the knees, ankles, arms, and legs.
The majority of warts are asymptomatic. They do, however, produce facial deformity and, in a small percentage of cases, regional discomfort. Plantar warts can be unpleasant due to the compression and friction, which can cause bleeding. If the plantar wart is large enough, it might affect a patient’s ability to walk and wear shoes.
The viruses multiply in the skin. If someone has a weakened immune system, their body is not always able to successfully fight them off. Other people have a greater risk of getting warts because they have more frequent contact with the viruses (IQWiG, 2019).
Common warts are found to be preferentially associated with HPV2. The small endophytic keratosis puncta-like variety may also be induced by HPV4 and the hyperproliferative papillomatous variety by HPV7.
Warts, in general, are benign, but there are reports that sometimes they may become malignant and develop into what is known as verrucous carcinoma. The verrucous carcinoma is a slow-growing tumor classified as a well-differentiated squamous cell malignancy that is often mistaken for a common wart. Even though it can occur on any part of the body, it is most common on the plantar surface. Verrucous cancer rarely spreads, but it is locally destructive (Aboud & Nigam, 2021).
The diagnosis of verruca vulgaris can be made after a small piece of the growth is removed in a procedure called a biopsy or after the entire growth is removed in a procedure called an excision. The tissue is then sent to a pathologist who examines it under the microscope.
There are numerous treatments for warts, and whether used stand alone or in combination, they often have a little evidence base for their use. Home remedies also abound and may have some reason for potential efficacy. The treatment strategies can be organized into three groups: physical or chemical destruction, immune-modulating agents, and antiproliferation agents.
Common Warts Epidemiology
The Common Warts epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight’s report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Common Warts epidemiology segmented as the Diagnosed Prevalent Cases of Common Warts, Gender specific Prevalence of Common Warts. The report includes the Prevalent scenario of Common Warts in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Country Wise- Common Warts Epidemiology
The epidemiology segment also provides the Common Warts epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total prevalent population of Common Warts associated in 7MM countries was estimated to be 14,868,561 cases in 2019 and expected to increase at a CAGR of 0.22% for the study period, i.e., 2019–2032.
• As per the estimates, US has the highest prevalent population of Common Warts in 7MM.
Among the EU-5 countries, Germany had the highest prevalent population of Common Warts. On the other hand, Spain had the lowest number of case, 1,636,252 cases in 2019.
Scope of the Report
• Common Warts report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
• Common Warts Epidemiology Report and Model provide an overview of the risk factors and global trends of Common Warts in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report provides insight into the historical and forecasted patient pool of Common Warts in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
• The report helps recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Common Warts.
• The report provides the segmentation of the Common Warts epidemiology by prevalent Cases of Common Warts in 7MM.
• The report provides the segmentation of the Common Warts epidemiology by Diagnosed Prevalent of Common Warts, Prevalence of Common Warts based on Gender specific factors in 7MM.

Report Highlights
• 11-year Forecast of Common Warts epidemiology
• 7MM Coverage
• Diagnosed Prevalent Cases of Common Warts
• Gender specific Prevalence of Common Warts

KOL Views
We interview KOLs, and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
• What will be the growth opportunities in the 7MM concerning the patient population about Common Warts?
• What are the key Findings of Common Warts epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2019–2032)?
• What would be the total number of patients with Common Warts across the 7MM during the forecast period (2019–2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019–2032)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019–2032)?
• What are the disease risk, burden, and unmet needs of Common Warts?
• What are the currently available treatments for Common Warts?

Reasons to buy
The Common Warts Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Common Warts market
• Quantify patient populations in the global Common Warts market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and gender that present the best opportunities for Common Warts therapeutics in each of the markets covered
• Understand the magnitude of Common Warts population by its prevalent cases
• Understand the magnitude of Common Warts population by its clinical manifestation specific cases
• The Common Warts epidemiology report and model was written and developed by Masters and PhD level epidemiologists
• The Common Warts Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 12-year forecast period using reputable sources

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2019–2032